
BW 245CDP1 receptor agonist |
Sample solution is provided at 25 µL, 10mM.
































Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure


BW 245C Dilution Calculator
calculate

BW 245C Molarity Calculator
calculate
Cas No. | 72814-32-5 | SDF | Download SDF |
Chemical Name | (4S)-(3-[(3R,S)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid | ||
Canonical SMILES | O=C(N1[H])[C@H](CCCCCCC(O)=O)N(CCC(O)C2CCCCC2)C1=O | ||
Formula | C19H32N2O5 | M.Wt | 368.5 |
Solubility | ≤50mg/ml in ethanol;50mg/ml in DMSO;50mg/ml in dimethyl formamide | Storage | Store at -20°C |
Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
Target: DP1 receptor
IC50: 2.5 nM
Ki: 0.9 nM
BW 245C is a kind of prostaglandin analogue with stable chemical properties which functions as a potent inhibitor of platelet aggregation. BW 245C could selectively active the DP1 receptor, and inhibit [3H]-PGD2 binding to isolated human platelet membranes, with the Ki value of 0.9 nM [1].
In Vitro: BW 245C could inhibit the aggregation of human and rat platelets induced by ADP in a dose dependent manner, with the IC50 values of 8.7 nM and 9.9 nM, respectively [1]. Besides, in HEK293 cells stably expressing the hDP receptor, BW 245C could significantly increase cAMP production, with the EC50 value of 0.7 nM [2].
In Vivo: In spontaneously hypertensive rats, intravenous bolus injection with BW 245C at the dose of 250 μg/kg could reduce the systolic and diastolic blood pressure by 23% and 34%, respectively [1].
Clinical trial: In four healthy male volunteers, intravenous injection of BW 245C (1, 2 and 4 ng kg-1 min-1) exerted a progressive increase in heart rate and pulse pressure [3].
References:[1] Town H C, Casalsstenzel J, Schillinger E, et al. Pharmacological and cardiovascular properties of a hydantoin derivative, BW 245 C, with high affinity and selectivity for PGD2 receptors[J]. Prostaglandins, 1983, 25(1): 13-28.[2] Boie Y, Sawyer N, Slipetz D, et al. MOLECULAR CLONING AND CHARACTERIZATION OF THE HUMAN PROSTANOID DP RECEPTOR[J]. Journal of Biological Chemistry, 1995, 270(32): 18910-18916.[3] Orchard M A, Ritter J M, Shepherd G L, et al. Cardiovascular and platelet effects in man of BW 245C, a stable mimic of epoprostenol (PGI2)[J]. British journal of clinical pharmacology, 1983, 15(5): 509-511.
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
大多数药物在体内都是和特异性受体相互作用,改变细胞的生理生化功能而产生效应。目前已经确定的受体有30多种,根据受体存在的标准,受体可大致分为三类:
1.细胞膜受体:位于靶细胞膜上,如胆碱受体、肾上腺素受体、多巴胺受体、阿片受体等。
2.胞浆受体:位于靶细胞的胞浆内,如肾上腺皮质激素受体、性激素受体。
3.胞核受体:位于靶细胞的细胞核内,如甲状腺素受体。
另外也可根据受体的蛋白结构、信息转导过程、效应性质、受体位置等特点将受体分为四类:
1.含离子通道的受体(离子带受体):如N-型乙酰胆碱受体含钠离子通道。
2.G蛋白偶联受体:M-乙酰胆碱受体、肾上腺素受体等。
3.具有酪氨酸激酶活性的受体:如胰岛素受体。
4.调节基因表达的受体(核受体):如甾体激素受体、甲状腺激素受体等。
有些受体具有亚型,各种受体都有特定的分布部位核特定的功能,有些细胞也有多种受体。
请教各位大神,我最近在做WB,565KD的蛋白,动物组织的样品,听说样品制备需要蔗糖裂解液,请问这个是必须的嘛?用一般蛋白提取方法制备可以吗?还有电泳和转膜条件能否分享一下。不胜感激

